|
T18805
|
Thalidomide-C2-amido-C2-COOH
|
Thalidomide-C2-amido-C2-COOH is a compound that includes a CRBN ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of PROTAC CDK2/9 Degrader-1[1].
|
|
T18873
|
VHL Ligand-Linker Conjugates 17
|
VHL Ligand-Linker Conjugates 17 are chemical compounds that consist of a VHL ligand specialized for the E3 ubiquitin ligase, as well as a PROTAC linker. These conjugates are utilized in the synthesis of various PROTACs, including the notable ARD-266. ARD-266 is an exceptionally effective androgen receptor (AR) PROTAC degrader[1].
|
|
T18661
|
(S,R,S)-AHPC-C10-NH2 dihydrochloride
|
(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-linker 10) 包含基于 (S,R,S)-AHPC 的VHL 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物，用于合成 BET 的靶向 PROTAC。
|
|
T18809
|
Thalidomide-NH-C6-NH2 TFA
|
Thalidomide-NH-C6-NH2 TFA is a synthetic conjugate compound that combines a cereblon ligand based on Thalidomide with a linker used in PROTAC technology, functioning as an E3 ligase ligand-linker conjugate[1].
|
|
T18811
|
Thalidomide-PEG2-C2-NH2 hydrochloride
|
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].
|
|
T17230
|
VH032-PEG3-acetylene
|
VH032-PEG3-acetylene is a synthesized conjugate compound consisting of a VH032-based VHL ligand and a linker, designed for use in PROTAC technology as an E3 ligase ligand-linker conjugate[1].
|
|
T18670
|
(S,R,S)-AHPC-Me-C5-COOH
|
(S,R,S)-AHPC-Me-C5-COOH is a synthetic E3 ligase ligand-linker conjugate consisting of a VHL ligand and a linker. It finds application in PROTAC DT2216[1].
|
|
T18672
|
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc
|
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is an E3 ligase ligand-linker conjugate, specifically designed for targeting the EED protein in PROTAC applications[1].
|
|
T18813
|
Thalidomide-PEG2-C2-NH2
|
Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].
|
|
T18673
|
(S,R,S)-AHPC-O-Ph-PEG1-NH2
|
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) serves as an E3 ligase ligand-linker conjugate, integrating a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. This compound is utilized in PROTAC EED degrader-1, a PROTAC that targets EED with a potency (pKD) of 9.02[1].
|
|
T18660
|
(S,R,S)-AHPC-amido-C5-acid
|
(S,R,S)-AHPC-amido-C5-acid is a chemical compound that contains a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. It can be utilized in the design of XY028-133[1].
|
|
T18808
|
Thalidomide-NH-C4-NH2 TFA
|
Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2/BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].
|
|
T18825
|
Thalidomide-O-C6-NH2
|
Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].
|
|
T18663
|
(S,R,S)-AHPC-C3-NH2 TFA (2361119-88-0 free base)
|
(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, suc
|
|
T18665
|
(S,R,S)-AHPC-C4-NH2 dihydrochloride
|
(S,R,S)-AHPC-C4-NH2 dihydrochloride is a chemically derived E3 ligase ligand-linker conjugate, consisting of the (S,R,S)-AHPC VHL ligand and a linker specifically designed for EED-Targeted PROTAC[1].
|
|
T18815
|
Thalidomide-O-amido-C4-NH2 hydrochloride
|
Thalidomide-O-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a linker. It is commonly employed in the synthesis of PROTACs[1].
|
|
T18667
|
(S,R,S)-AHPC-C5-COOH
|
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a Kd of 185 nM, has the potential for the study of anemia and ischemic diseases[1].
|
|
T18810
|
Thalidomide-NH-C6-NH2
|
Thalidomide-NH-C6-NH2 is a synthetic conjugate compound designed as an E3 ligase ligand-linker. It consists of a Thalidomide-based cereblon ligand linked to a specific linker utilized in PROTAC technology[1].
|
|
T18822
|
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride
|
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride 是一种合成的 E3 连接酶配体- linker 偶联物，包含基于 Thalidomide 的 cereblon 配体和 linker 。
|
|
T18662
|
(S,R,S)-AHPC-C2-PEG4-N3
|
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate combining the (S,R,S)-AHPC-based VHL ligand with a 4-unit polyethylene glycol (PEG) linker, employed in PROteolysis TAgeting Chimera (PROTAC) technology. This compound facilitates the creation of vRucaparib-TP4, a potent PARP1 degrader demonstrating a half-maximal degrading concentration (DC50) of 82 nM[1].
|
沪公网安备 31010602004043号
